Probucol

Overview

Probucol, sold under the trade name Lorelco among others, is an lipid-lowering agent initially developed for the treatment of coronary artery disease. Clinical use was discontinued in some countries after it was found that the drug may have the undesired effect of lowering HDL-C in patients with a previous history of heart disease. It may also cause QT interval prolongation.[1–4] WP

Probucol was originally developed as an industrial antioxidant added to tires to maximize their longevity.[5] WP

Uses, dosage and effects

Medical uses

In Japan, it is approved for "hyperlipidemia (including familial hypercholesterolemia and xanthomas)". In China, it is approved for hypercholesterolemia.[6][7][8] WP

Risks and side effects

Adverse effects

During both clinical trials and postmarketing surveillance, most adverse effects were limited to the digestive system and the skin. Those included diarrhea, abdominal pain, nausea, loss of appetite, rash, and itching. For each of these effect, the incidence was between 0.1% and 1% ("uncommon"). QT prolongation was noted as rare (< 0.1%) in the package inserts. Elevated liver enzymes (ALT, AST, ALP, LDH), elevated BUN, reduction in red blood cells, white blood cells, and/or platelet count, elevated creatine kinase are also possible. The Chinese package insert states that ALT, AST, bilirubin, uric acid, and BUN elevations are transient.[6][7][8] WP

Possible serious adverse effects include ventricular arrhythmia (Torsades de pointes), syncope, gastrointestinal bleeding, peripheral neuritis, and rhabdomyolysis. The frequency of these are unknown.[6][7] WP

Interactions

Drug interactions

May reduce the blood concentration of cyclosporin (unknown mechanism). There exist reports of significantly declined HDL-C with clofibrate (unknown mechanism).[6] WP

Risk of arrhythmia is elevated when used with other drugs that can cause arrhythmia, especially tricyclic antidepressants and phenothiazines. Potentiates the effect of diabetic medications and coumarin anticoagulants.[8] WP

Pharmacology

Mechanism of action

Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Specifically, this happens by changing the structure of LDL, among other effects. The LDL receptor is not involved: it works in rabbits and humans without a working LDL receptor (homozygous familial hypercholesterolemia). It also enhances the excretion of cholesterol into bile. It is able to lower LDL-C by 10-20%.[2] WP

It is also a powerful antioxidant. At a low dose (insufficient to affect LDL-C or HDL-C levels), it prevents the oxidation of cholestrol in LDLs. This might slow the formation of foam cells, which form atherosclerotic plaques. It partially does this by increasing PON1 activity, thus increasing the antioxidant properties of HDL.[2][9] WP

Probucol also lowers HDL-C (HDL cholesterol, i.e. the amount of cholesterol found in HDLs) by about 30%. This has historically caused its discontinuation from several Western countries. This has several causes:[2] WP

• It inhibits ABCA1-dependent cholesterol transport (but not SR-BI–mediated efflux), which moves cholesterol from cells such as macrophages into HDL.[10] WP
• It increases CETP activity by lowering the amount of ANGPTL3. This also causes an increase in preβ1-HDL (lipid-poor particles) and a decrease in HDL phospholipids.[11][12] WP
• It increases HDL absorption by the liver via SR-BI.[2] WP

Recall that one of the functions of HDL is reverse cholesterol transport (moving cholesterol from peripheral tissues into the liver). Inhibition of ABCA1 would be detrimental to the process, whereas enhancing CETP and SR-BI activities is beneficial for the transport function. Overall, probucol increases the capacity for reverse cholesterol transport, so the observed HDL-C reduction does not lead to a decrease in a patient's cholesterol-removing ability.[2] WP

The adverse effect of QT prolongation is possibly due to inhibition of hERG trafficking.[4] WP

Pharmacokinetics

Oral absorption is limited and erratic. Food increases absorption. With a single oral dose of 250 mg, tₘₐₓ is at 18 hours post-ingestion. If taken daily, 3 to 4 months are required to reach steady-state concentrations.[6][8] WP

The tissue distribution of probucol has been studied in rats, dogs, and monkeys using a ¹⁴C-labelled version of the drug. In rats, a single 100 mg/kg dose results in liver, adrenal glands, and brown fat concentrations at 3–10× plasma concentration and central nervous system, gonad, and eye concentrations at 1/7–1/20× plasma concentration. In rats, 21 days of continuous 100 mg/kg/d feeding results in accumulation in brown fat, adrenal glands, liver, and adipose tissue at 10–46× plasma concentration and central nervous system, gonad, and eye concentrations at 1–1/2× plasma concentration.[6] WP

Research

Research

Probucol has been found to have antioxidant and anti-inflammatory properties via several different mechanisms. These properties have led to research into the drug's potential capacity to treat sensorineural hearing loss related to oxidative stress, as well as formulations to improve the delivery of the drug into the ear.[13][14] WP

After promising test results in mouse models, probucol is under study at Weston Brain Institute of McGill University as a possible aid in delaying the onset of Alzheimer's disease. The protocol for a future Australian Phase II study was published in 2022.[15] WP⚠ Wikipedia itself has flagged this text: citation needed.

Novel packaging methods have been tried to optimize the pharmacokinetic properties of probucol – the goal is usually to produce a more stable absorption profile and to reduce absorption by cardiac muscle cells. Some show promise in lab animals, but have not yet been tested in humans.[16] WP

Analogues

A number of probucol analogues have been tested in animal models by researchers seeking to optimize aspects of probucol's action while reducing its side effects. Succinobucol, the succinate ester of probucol, failed to demonstrate a useful degree of efficacy in clinical trials targeting acute coronary syndrome. BO-653, another analogue, failed its phase II trial targeting atherosclerosis treatment and prevention of post-angioplasty restenosis.[16] WP

Legal status

Society and culture

In Japan, Probucol was available under both the Lorelco brand name, the Sinlestal brand name, and the generic "TOWA" brand. In January 2021, Towa Pharmaceutical Co., Ltd. announced that it would discontinue the sale of Probucol Tablets 250 mg "TOWA" due to various circumstances.[17] WP

Chemistry

Formula

C31H48O2S2 PC

CAS number

23288-49-5 PC

Molar mass (g/mol)

516.8 PC

IUPAC name (computed by PubChem)

2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol PC

SMILES

CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C PC

InChIKey

FYPMFJGVHOHGLL-UHFFFAOYSA-N PC

PubChem CID

4912

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Yamamoto A. A Unique Antilipidemic Drug - Probucol. Journal of Atherosclerosis and Thrombosis. 11 December 2008. doi:10.5551/jat.E621 · PMID 19075491
2. Journal / agency Yamashita S, Masuda D, Matsuzawa Y. Did we abandon probucol too soon?. Current Opinion in Lipidology. August 2015. doi:10.1097/MOL.0000000000000199 · PMID 26125504
3. Journal / agency Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis. November 2009. doi:10.1016/j.atherosclerosis.2009.04.002 · PMID 19457483
4. Journal / agency Mamoshina P, Rodriguez B, Bueno-Orovio A. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Reports. March 2021. doi:10.1016/j.xcrm.2021.100216 · PMID 33763655 · PMC7974548
5. Journal / agency Yamashita S, Masuda D, Matsuzawa Y. New Horizons for Probucol, an Old, Mysterious Drug. Journal of Atherosclerosis and Thrombosis. February 2021. doi:10.5551/jat.ED132 · PMID 32507832 · PMC7957029
6. Other ロレルコ錠250mg/ロレルコ細粒50% 添付文書 第15版
7. Other シンレスタール錠250mg/シンレスタール細粒50% 添付文書. November 2011
8. Other 普罗布考片
9. Journal / agency Inagaki M, Nakagawa-Toyama Y, Nishida M, Kawase R, Kawase M, Nakaoka H, Nakatani K, Yamashita T, Tsubakio-Yamamoto K, Masuda D, Ohama T, Ishigami M, Yamashita S, Komuro. Abstract 12669: Effect of Probucol on Antioxidant Properties of HDL in Patients with Heterozygous Familial Hypercholesterolemia. Circulation. 22 November 2011. doi:10.1161/circ.124.suppl_21.A12669
10. Journal / agency Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler. Thromb. Vasc. Biol. 28 October 2004. doi:10.1161/01.ATV.0000148706.15947.8a · PMID 15514211
11. Journal / agency Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis. October 2008. doi:10.1016/j.atherosclerosis.2007.12.031 · PMID 18279878
12. Journal / agency Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori CR. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 1989. doi:10.1161/01.ATV.9.4.462 · PMID 2751476
13. Journal / agency Chester J, Johnston E, Walker D, Jones M, Ionescu CM, Wagle SR, Kovacevic B, Brown D, Mikov M, Mooranian A, Al-Salami H. A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology. Pharmaceutics. July 2021. doi:10.3390/pharmaceutics13071041 · PMID 34371732 · PMC8309044
14. Journal / agency Wagle SR, Ionescu CM, Kovacevic B, Jones M, Foster T, Lim P, Lewkowicz M, Ðanić M, Mikov M, Mooranian A, Al-Salami H. Pharmaceutical characterization of probucol bile acid-lithocholic acid nanoparticles to prevent chronic hearing related and similar cellular oxidative stress pathologies. Nanomedicine. May 2023. doi:10.2217/nnm-2023-0092 · PMID 37529927
15. Journal / agency Lam V, Clarnette R, Francis R, Bynevelt M, Watts G, Flicker L, Orr CF, Loh P, Lautenschlager N, Reid CM, Foster JK, Dhaliwal SS, Robinson S, Corti E, Vaccarezza M, Horgan B, Takechi R, Mamo J. Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). BMJ Open. February 2022. doi:10.1136/bmjopen-2021-058826 · PMID 35190446 · PMC8860076
16. Journal / agency Sharif A, Mamo J, Lam V, Al-Salami H, Mooranian A, Watts GF, Clarnette R, Luna G, Takechi R. The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases. Translational Neurodegeneration. January 2024. doi:10.1186/s40035-024-00398-w · PMID 38247000 · PMC10802046
17. Other Notice of Discontinuation of Probucol Tablets 250mg "TOWA"

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.